EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
2013/10/25 by Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld +44 · 29 citations
Medicine · Immunology and Microbiology · #Rheumatoid Arthritis Research and Therapies #Biosimilars and Bioanalytical Methods #Lymphoma Diagnosis and Treatment
paper · pdf · doi:10.1136/annrheumdis-2013-204573
Cited by
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
- Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
- Methotrexate for treating rheumatoid arthritis. [europepmc]
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. [europepmc]
- Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. [europepmc]
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. [europepmc]
- The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. [europepmc]
- Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis. [europepmc]
- Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. [europepmc]
- Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. [europepmc]
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. [europepmc]
- A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. [europepmc]
- The changing landscape of biosimilars in rheumatology. [europepmc]
- Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. [europepmc]
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. [europepmc]
- Improved survival in rheumatoid arthritis: a general population-based cohort study. [europepmc]
- Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. [europepmc]
- Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. [europepmc]
- Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. [europepmc]
- Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. [europepmc]
- Preventing progression from arthralgia to arthritis: targeting the right patients. [europepmc]
- Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis. [europepmc]
- A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. [europepmc]
- Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. [europepmc]
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. [europepmc]
- Hydroxychloroquine in rheumatic autoimmune disorders and beyond. [europepmc]
- Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. [europepmc]